CTIS2022-503146-53-00招募中1 期
1404-0014
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
进行中（未招募）
1 期
A study to test how well different doses of BI 1584862 are tolerated by healthy meHealthy volunteer trialMedDRA version: 20.0Level: SOCClassification code: 10015919Term: Eye disorders Class: 9CTIS2023-503541-54-00Boehringer Ingelheim International GmbH50
进行中（未招募）
1 期
A study in healthy men to test whether itraconazole influences the amount of BI 1584862 in the bloodHealthy volunteer trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2023-503542-31-00Boehringer Ingelheim International GmbH14
进行中（未招募）
1 期
A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancereuroendocrine carcinoma (NEC) or small cell carcinoma of any otherorigin, Small cell lung carcinoma (SCLC), Large cells neuroendocrine lung carcinoma (LCNEC)MedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2022-501818-54-00Boehringer Ingelheim International GmbH12
进行中（未招募）
1 期
A study in healthy men to test how BI 764198 is processed in the bodyHealthyMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2022-502327-22-00Boehringer Ingelheim International GmbH16